Doximity's AI Story Is Real. The Stock Just Ran Ahead of the Story.

# Doximity's AI Story Is Real. The Stock Just Ran Ahead of the Story.

Three weeks ago, Doximity did something that doesn't happen often on Wall Street: it beat, guided up, and the market rewarded it with a violent, no-half-measures 30%+ single-day pop. That's the kind of move that gets a stock trending on every finance app in America. It's also the kind of move that, three weeks later, deserves a much colder look than the euphoria allowed.

Here's the state of play. On August 6–7, Doximity reported fiscal Q1 2027 revenue of $156.62 million, up 7.3% year-over-year, comfortably ahead of estimates. Adjusted EBITDA came in at $74.77 million — a 47.7% margin — beating the Street's $69.59 million estimate by better than 7%. Management nudged full-year revenue guidance higher and, crucially, leaned hard into the AI narrative: roughly half of the company's 800,000+ active prescriber base is now using its clinical AI tools. The stock, which had been limping around $17 after a brutal May selloff, tore straight up to the mid-$20s. As of mid-August it was sitting near $24.94, up nearly 16% on the month and better than 25% over ninety days.

That May selloff, by the way, is worth remembering precisely because everyone's forgotten it. Doximity posted a genuinely strong Q4 FY2026 — record engagement, $317.5 million in free cash flow, up 19% — and the stock got crushed anyway because FY2027 guidance of $664–$676 million came in light and adjusted EPS missed by two cents. The lesson: this stock does not get credit for good quarters in isolation. It gets punished for cautious outlooks and rewarded for confident ones, full stop. Which means the entire multi-month arc from $17 to $26 has been a referendum on tone, not just numbers.

So is the tone still justified up here? That's where it gets interesting.

The bull case hasn't gone anywhere: 85%+ of U.S. physicians on the platform, a genuine AI adoption story that's showing up in actual usage stats rather than just slideware, EBITDA margins near 48%, and a business that throws off cash like a mature software company because, structurally, that's exactly what it is. Barclays bumped its price target from $20 to $27 on the print, and the broader consensus target drifted up to around $28. None of that is fantasy.

But three things should keep you from chasing this above $26. First, the growth rate itself — 7.3% — is fine, not thrilling, for a stock now trading north of 16x forward earnings with a PEG pushing 2.6 on decelerating growth in the low-double-digits. The multiple-expansion trade — buying a beaten-down stock and letting sentiment do the work — is largely finished. What's left has to come from fundamentals actually accelerating, not just beating conservative bars.

Second, and more pointedly: insiders aren't buying this rally, they're selling into it. Three insider sales totaling roughly $387,000 in the twenty days after the print — a director, the CAO, another director — and exactly zero buys. That's not a scandal, but it's a tell. People who actually run the company are treating $25+ as a level to lighten up, not load up.

Third, the fuel that powered a chunk of this move — short interest — has compressed from roughly 20% of float down to 15%. That's squeeze ammunition that's already been spent. The next leg, if there is one, needs to come from the business, not from shorts capitulating.

Put it together and you get a stock that did exactly what it needed to do in August, priced in most of the good news immediately, and now has to wait roughly ten weeks for the next real catalyst: the Q2 FY2027 print, expected around early November, against a guide of roughly $170–171 million in revenue. Until then, this is a name to own on weakness, not chase on strength — accumulate in the $22–24 zone if the market offers it, and treat anything above $30 as a gift to the sellers, not an invitation to join the party late.

Doximity's fundamentals earned this rally. They haven't yet earned the next one.